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E-mail address: francisco.azuaje@crp-sante.lu (F. AThe discovery of novel disease biomarkers is a crucial challenge for translational bioinformatics. Demon-
stration of both their classiﬁcation power and reproducibility across independent datasets are essential
requirements to assess their potential clinical relevance. Small datasets and multiplicity of putative bio-
marker sets may explain lack of predictive reproducibility. Studies based on pathway-driven discovery
approaches have suggested that, despite such discrepancies, the resulting putative biomarkers tend to
be implicated in common biological processes. Investigations of this problem have been mainly focused
on datasets derived from cancer research. We investigated the predictive and functional concordance of
ﬁve methods for discovering putative biomarkers in four independently-generated datasets from the car-
diovascular disease domain. A diversity of biosignatures was identiﬁed by the different methods. How-
ever, we found strong biological process concordance between them, especially in the case of methods
based on gene set analysis. With a few exceptions, we observed lack of classiﬁcation reproducibility using
independent datasets. Partial overlaps between our putative sets of biomarkers and the primary studies
exist. Despite the observed limitations, pathway-driven or gene set analysis can predict potentially novel
biomarkers and can jointly point to biomedically-relevant underlying molecular mechanisms.
 2011 Elsevier Inc. All rights reserved.1. Introduction
The discovery of potential biomarkers for detecting, predicting
and supporting the treatment of diseases is a central aim to achieve
a more personalized, cost-effective medicine [1–4]. The traditional
approach to identifying putative biomarkers is based on the pre-
mise that genes and proteins act in isolation to contribute to the
emergence of speciﬁc phenotypes [1,5,6]. This has focused on the
detection of differentially expressed genes across clinical condi-
tions (classes) at a pre-deﬁned statistical signiﬁcance level and
after adjusting statistics for multiple-hypothesis testing [7–9].
The notion that common complex diseases rise and progress
through the reciprocal actions of multiple genes has motivated the
application of advanced methodologies that look at biologically-ll rights reserved.
ting curve; HF, heart failure;
; ISC, ischemic heart failure;
rst GEO dataset used in DCM
dataset used in DCM vs. NF
ed in ISC vs. NF classiﬁcation
s. NF classiﬁcation problem;
, semantic similarity.
zuaje).meaningful ‘‘gene sets’’, rather than lists of independently-
assumed genes [10–12]. In this area, different methods based on
the deﬁnition of scores or indices to summaries the gene expres-
sion activity of a gene set at the sample (patient) and class levels
have been proposed [13,14]. Such measures encapsulate different
aspects of gene set- or pathway-based activity, including statistics
based on gene set-class correlations, gene expression means, be-
tween-gene correlations, etc. [15,16]. Using this information,
researchers can statistically detect differentially expressed gene
sets or annotated pathways for supporting biomarker and drug tar-
get discovery research [16,17]. The data linked to the genes deﬁn-
ing these sets, or the global scores assigned to these sets, have been
used as inputs to subsequent discovery tasks [18,19]. Disease clas-
siﬁcation and prediction is one such task, which aims to develop
new computer-based systems for decision support: disease diag-
nosis, prognosis, prediction of responses to therapies and surrogate
end-points in clinical trials [1,20–22].
The possible acceptance of disease biomarkers and derived clas-
siﬁcation models by the clinical community depends on two cru-
cial factors [23–25]: its prediction or discrimination capacity, and
the reproducibility of such performance across patient cohorts or
independent datasets. These factors are fundamental initial steps
to assess the potential clinical relevance of new biomarkers and
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investigations reported to date have shown great promise with re-
gard to prediction performance [23]. Unfortunately, the task of
demonstrating this in independent, multi-site evaluations has pro-
ven to be a greater challenge [23]. A reliance on small datasets,
experimental sources of error and bias, inconsistencies across lab-
oratory protocols and variance added by data pre-processing pro-
cedures have been considered as viable factors inﬂuencing poor
predictive reproducibility [28–30]. This problem can also be seen
as a consequence of the multiplicity of biomarkers or signatures
identiﬁed by different methods, across different studies dealing
with the same clinical problem or even using the same dataset
[27,31,32].
Recent research has suggested that the application of gene set
analysis may contribute to improving both prediction capacity
and reproducibility [33,34]. Moreover, investigations have
revealed that, despite the relative small agreement or overlap
between biomarkers indentiﬁed by different methodologies, gene
set analysis can point to signiﬁcant underlying functional com-
monalities in the form of shared biological processes [32–35]. Pre-
vious studies in this area have focused on datasets originating from
cancer research [27,34,35]. Furthermore, some of these studies
have concentrated on the characterization of the genes or path-
ways shared by the disease signatures detected by different meth-
ods [34,36]. We set to investigate the problems of predictive
performance and reproducibility in the area of cardiovascular
research.
We aim to compare different gene set analysis approaches using
several independently-generated genome-wide expression data-
sets from published investigations of human heart failure (HF).
We assessed the predictive power of the resulting putative bio-
markers through the implementation of classiﬁcation models,
cross-validation and independent evaluations. Furthermore, we
look at the biological concordance between methods within and
between datasets. Our study shows the robustness of gene set
analysis in connection to such integrative, functional relationships.Fig. 1. Overview of research framework. A. Analysis pipeline for assessing functional an
Description of datasets and biomarker discovery methods investigated. GEO accession nHowever, a less clear picture unfolds when evaluating classiﬁca-
tion performance across independent datasets. Notwithstanding
these disagreements, we found partial agreements between our
investigations and the original (primary) studies using different
methodologies. Finally, we show potentially novel biomarkers
and associations that will require additional research, and discuss
issues possibly inﬂuencing the observed discrepancies.2. Methods
2.1. Research framework
Fig. 1 summarizes the main components and steps of our inves-
tigations. After preparing the datasets, we applied ﬁve putative
biomarker discovery techniques, whose most-statistically signiﬁ-
cant outcomes (gene sets and gene lists) were analyzed in terms
of Gene Ontology (GO) biological process annotations. We
searched for statistically signiﬁcant overlaps between these results
within each data and across datasets with the same case-control
conditions. Using the top gene sets and genes, we implemented
classiﬁcation models and estimated their performance using
leave-one-out cross-validation (LOOCV) on the derivation dataset,
and an evaluation on a second, independently-generate dataset.
The sequence of this analysis pipeline is illustrated in Fig. 1A.
The clinical diagnostic problems, datasets and biomarker discovery
methodologies investigated are shown in Fig. 1B, and are described
in detail as follows.2.2. Datasets investigated
We concentrated on two classiﬁcation problems relating to the
diagnosis of human HF. The ﬁrst problem aims to distinguish
between patients with dilated cardiomyopathy (DCM), which is a
type of HF, and those with non-failing hearts (NF). The second
application deals with the classiﬁcation of ischemic (ISC) HF vs.d predictive concordance of different methods to discover putative biomarkers. B.
umbers are provided for each dataset.
Table 1
Description of datasets investigated. GEO accession numbers. DCM: dilated cardio-
myopathy, NF: non-failing heart, ISC: ischemic heart failure.
Dataset Clinical classes # of genes # of samples
(classes A and B)
Refs.
GDS2205 DCM vs. NF 8021 12 (7, 5) [36]
GDS2206 DCM vs. NF 21,389 28 (13, 15) [36]
GSE1869 ISC vs. NF 12,997 16 (10, 6) [37]
GSE5406 ISC vs. NF 12,997 124 (108, 16) [38]
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generated gene expression datasets reported in [37–39]. Normal-
ized data were obtained from the Gene Expression Omnibus
database (GEO). We re-scaled expression values across samples
so that mean and standard deviation were equal to 0 and 1 respec-
tively. Table 1 lists the main characteristics of these datasets,
including their GEO accession numbers and clinical class structure.
In total, we analyzed approximately 2.5 million gene expression
values across 180 heart tissue samples. In the DCM vs. NF classiﬁ-
cation problem, the GDS2205 and GDS2206 datasets included 7
and 13 DCM samples respectively, together with 5 and 15 NF sam-
ples respectively. In the ISC vs. NF classiﬁcation application, the
GSE1869 (ArrayExpress number: E-GEOD-1869) and GSE5406
(ArrayExpress number: E-GEOD-5406) datasets offered 10 and
108 ISC samples respectively, together with 6 and 16 control
(NF) cases. All samples were derived from left ventricle biopsies.
From now on, we will refer to these datasets using their accession
numbers.
In each clinical application setting, the development of disease
classiﬁcation models consisted of two main phases: Model deriva-
tion and independent evaluation. The derivation phase involves
model building (training) and testing through LOOCV. The inde-
pendent evaluation comprised the application of the models ob-
tained from the derivation phase to a second dataset not
included in the derivation phase. In the DCM vs. NF classiﬁcation
problem, GDS2205 and GDS2206 were used as derivation and
independent datasets respectively, and then vice versa. The same
dataset selection–evaluation procedure was implemented in the
ISC vs. NF biomarker discovery application.
2.3. Putative biomarker discovery methods investigated
Five published techniques for the identiﬁcation of putative
biomarker discovery using gene expression data were investigated
(Fig. 1B): Gene Set Enrichment Analysis (GSEA) [15], two pathway-
centric analysis techniques from the kipuMarkers methodology
[16], SimTrek: a GO-based similarity gene set analysis technique
[40], and empirical Bayes analysis for detecting differentially
expressed genes [41].
For a given gene set, G: {g1, g2, . . ., gn}, the GSEA method esti-
mates a enrichment score for G based on the Kolmogorov–Smirnov
statistic [15], which reﬂects the differential correlation between G
and the phenotype classes under consideration. GSEA is one of the
most-used gene set analysis techniques currently available. False
discovery rates for each G detected are estimated with a pheno-
type-based permutation procedure, as detailed in [15]. We concen-
trated our functional and classiﬁcation model building analyses on
the ﬁve most signiﬁcant gene sets (FDR 6 0.01).
Given G, the kipuMarkers-1 technique maps sample-speciﬁc
gene expression data on the input pathways, and scores each
pathway with the mean expression values observed in each
sample. The pathway-based scores, also referred to as gene set
activity levels, are then used to detect differential associations with
the phenotypes studied. Differential pathway-centric expression
levels are quantiﬁed as perturbation scores, and are computed usingthe t-statistic. Statistical control for multiple-testing is imple-
mented using a permutation procedure [16]. A variation of this
methodology, kipuMarkers-2, estimates a pathway activity level
by computing the mean of the pair-wise differences of expression
values observed in G, normalized to the size of the pathway.
Perturbation scores for each pathway and statistical testing are
implemented as in kipuMarkers-1. We concentrated our functional
and classiﬁcation model building analyses on the ﬁve most
signiﬁcant gene sets (FDR 6 0.01).
In this research GSEA, kipuMarkers-1 and kipuMarkers-2 used a
collection of 639 molecular pathways from the Molecular Signa-
tures Database (MSigDB) [15]. Our predictions concentrated on
its ‘‘C2 collection’’ of canonical pathways, which integrates anno-
tated signaling and metabolic pathways obtained from different
manually-curated databases.
Unlike GSEA and kipuMarkers, the SimTrek technique does not
require gene sets as user-deﬁned inputs. Given a seed list of gene
products, G: {g1, g2, . . ., gn}, gene sets: Gg1, Gg2, . . ., Ggn, are assem-
bled for each gene in G using the GO-based functional similarity
between gi and other genes in the genome. The nearest neighbors
in this ‘‘semantic’’ space are retrieved as the predicted gene set for
each query gene. Thus, for a given list of query genes, SimTrek pre-
dicts gene sets that can be subsequently analyzed using expression
data corresponding to their constituent genes. SimTrek computes
whole-genome, GO-based functional similarity using information
theoretic methods, as explained in [40]. SimTrek has shown its po-
tential to infer relevant gene sets, including putative protein–
protein interactions [40]. In this study, SimTrek processed the 10
genes most differentially expressed as its input queries. Differen-
tially expressed genes were identiﬁed with the empirical Bayes
method [41]. For each query gene, SimTrek generated gene sets
consisting of the 10-nearest neighbors in the GO-based similarity
space, using non-IEA (not Inferred from Electronic Annotations)
Biological Process GO terms and human genes only. Thus, SimTrek
predicted for each dataset (up to) 10 gene sets, each comprising
(up to) 10 putative biomarkers.
To expand our investigation beyond gene set analysis, we report
differentially expressed genes as putative biomarkers identiﬁed by
a linear model method based on the Empirical Bayes moderate
t-statistic [41]. After ﬁtting a linear model to the expression proﬁle
of each gene in a dataset, standard errors are moderated applying
an Empirical Bayes model. A moderated t-statistic and a log-odds
of differential expression is then computed for each contrast for
each gene. Empirical Bayes has shown predictive robustness even
in small size datasets [41], and has been successfully applied to
support systems biology research [42]. Here we focused on the
top-100 differentially expressed genes detected by this method,
with all of them reporting P < 0.01.
2.4. Bioinformatic tools and statistics
Analyses with GSEA, kipuMarkers and SimTrek were imple-
mented with Java-based software provided by their authors
[15,16,40]. Linear models based on moderated t-statistics and
Empirical Bayes analyses were implemented using the R software
package, Limma library from Bioconductor [43]. Statistically
detectable overlaps between putative biomarker sets, in terms of
their GO annotations, were estimated with the Java-based software
ToppCluster [44]. This system applies the hypergeometric test and
multiple-testing corrections to detect statistically detectable GO
term enrichments. We focused on signiﬁcant enrichments with
FDR 6 0.01. All other statistical measures reported were adjusted
for multiple-testing as indicate above. Classiﬁcation models were
implemented with the Weka data mining platform [45,46]. Due
to its demonstrated classiﬁcation performance and robustness,
we focused on models based on linear Support Vector Machines
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rithm (complexity parameter = 1, exponent = 1) [46,47]. Classiﬁca-
tion performance was summarized with areas under the receiving
operating characteristic curves (AUCs). Associations between sets
of putative biomarkers and prior biomedical knowledge were
examined using published literature and Pubmed.3. Results
3.1. Discovery of clinically-relevant biological pathways
In GDS2205, the gene set analysis methods detected diverse sig-
niﬁcantly altered pathways, as annotated in the MSigDB: From
metabolism, immune responses to protein synthesis (Table S1 in
Supplementary information). Overall GSEA, kipuMarkers-1 and
kipuMarkers-2 shared metabolism-related pathways as the most
signiﬁcant perturbations. Unlike GSEA, the kipuMarkers tech-
niques positioned immune response pathways (such as those
involved in immune cell control) at the top of the most differen-
tially altered gene sets across DCM and NF patients. GSEA
top-ranked pathways more speciﬁcally involved in protein biosyn-
thesis and energy metabolism (Table S1). In GDS2206, this prefer-
ence toward metabolic, immune response and protein synthesis
pathways was preserved (Table S2). Nevertheless, kipuMarkers-1
and kipuMarkers-2 highlighted the alteration of cell death pro-
cesses (e.g. apoptosis and CD40 pathways). GSEA ranked speciﬁc
pathways involved in amino acid metabolism as top perturbations
underlying HF (e.g. degradation of valine and leucine).
In GSE1869, kipuMarkers-1 detected strong perturbations in
calcium regulation in cardiac cells and smooth muscle contraction
(as deﬁned in the MSigDB) (Table S3). kipuMarkers-v2 highlighted
differential alternations in molecular signaling processes known to
be implicated in cancers (e.g., estrogen signaling and cell migration
of carcinoma cells, Table S3). GSEA emphasized the deregulation of
pathways responsible for transmembrane signal transduction (e.g.,
G protein-coupled receptor interactions). kipuMarkers-1 detected
major alterations in pathways relevant to sugar metabolism (e.g.,
streptomycin biosynthesis and starch metabolism). kipuMarkers-
v2 and GSEA pointed to pathways implicated in inﬂammation
and responses to infections (e.g., CCR3 and cytokine interaction
pathways). In GSE5406, all the methods indentiﬁed signiﬁcant
alternations in amino acid synthesis and energy metabolism path-
ways (Table S4). In the list of top perturbations, these methods also
positioned pathways directly implicated in cell division and migra-
tion, including those deregulated in different cancers, e.g., ERK and
RECK. These methods also detected important perturbations in
pathways required for cellular death (e.g., Tall 1 pathway). GSEA
was capable to pinpoint heart-speciﬁc perturbations, e.g. insulin
receptor and PIP3 signaling in cardiac myocytes.3.2. Intra-dataset, process-oriented concordance of putative biomarker
discovery methods
In each dataset we performed a closer examination of poten-
tially signiﬁcant functional overlaps between the methods on the
basis of shared GO Biological Process terms. We look at the statis-
tical enrichment of GO terms observed in the top-perturbed path-
ways reported above. This analysis also included the putative
biomarkers detected by the methods not driven by pathway anal-
ysis (semantic similarity and empirical Bayes). Figs. 2 and 3 illus-
trate examples of such a functional concordance within the same
datasets. In these ﬁgures, methods and GO Biological Process terms
are depicted with circles and squares, respectively. Lines are used
to show signiﬁcant statistical associations between methods and
the (top-10) shared GO terms (FDR 6 0.01). The darker the linethe stronger the GO term enrichment detected by a method. Alter-
native visualizations of these ﬁgures are included in the Supple-
mentary information (Tables S8 and S9).
In both GDS2205 and GDS2206 datasets (DCM vs. NF classiﬁca-
tion), stronger agreements between kipuMarkers-1, kipuMarkers-2
and GSEA can be observed (Fig. 2). Semantic similarity and empir-
ical Bayes showed relatively little overlaps between them and with
the pathway-driven methods. These results corroborated, for
example, the shared capacity of kipuMarkers-1, kipuMarkers-2
and GSEA to point to the signiﬁcant deregulation of metabolic
and immune processes.
Similar functional overlapping patterns were observed
in GSE1869 and GSE5406 (ISC vs. NF classiﬁcation, Fig. 3).
kipuMarkers-1, kipuMarkers-2 and GSEA tended to point to similar
perturbations. In these cases, however, the semantic similarity
method seemed to have more commonalities with kipuMarkers-
1, kipuMarkers-2 and GSEA in comparison to the previous analyses,
and to the empirical Bayes method. The strongest agreements be-
tween all the ﬁve methods were observed in processes required for
energy metabolism, immune responses and signal transduction
(GSE1869, Fig. 3A). In GSE5406 (Fig. 3B), a strong convergence of
pathway-driven methods was observed in processes related to cell
proliferation and cell death. In the list of most signiﬁcantly en-
riched GO terms, semantic similarity and empirical Bayes tech-
niques showed relatively weak concordance between them and
in relation to the other methods.
3.3. Inter-dataset, process-oriented concordance of putative biomarker
discovery methods
After investigating the intra-dataset agreement between meth-
ods, we characterized each dataset according to the GO Biological
Process term enrichments in the different gene lists and gene sets
detected by the methods. This allowed us to estimate statistically
detectable overlaps between datasets independently of the method
applied. Despite the multiplicity of genes and gene sets detected by
each method within each dataset, we found strong functional con-
cordance between them, within each disease classiﬁcation prob-
lem. Fig. 4 and Table S10 (Supplementary information) illustrate
these relationships for the 10-most statistically over-represented
GO terms.
In the DCM vs. NF classiﬁcation problem, different statistically
detectable functional overlaps between the putative biomarkers
from GDS2205 and GDS2206 were found (Fig. 4A). Examples of
these commonalities include signiﬁcant alterations in processes
implicated in cell death, metabolism and phosphorylation
(FDR < 0.01). In the ISC vs. NF classiﬁcation problem (Fig. 4B),
GSE1869 and GSE5406 allowed the extraction of putative biomark-
ers that are strongly implicated in common biological processes:
immune responses, cell proliferation, cell death and development
(FDR < 0.01).
3.4. Disease classiﬁcation capacity of putative biomarker discovery
methods
We tested the disease classiﬁcation capacity of the genes and
gene sets detected as signiﬁcantly, highly differentially expressed.
We built and tested support vector machine models based on the
expression data from the genes deﬁning an individual pathway
(GSEA) and gene set activity levels (kipuMarkers-1 and kipu-
Markers-2). We also evaluated classiﬁers based on different combi-
nations of genes detected by semantic similarity and empirical
Bayes methods. Models were built and tested (with LOOCV) on
each dataset separately (Section 2). Classiﬁcation performances
above an AUC = 0.80 (95% conﬁdence interval, CI: 0.54–1.0
(GDS2205), 0.63–0.97 (GDS2206), 0.56–1.0 (GSE1869), and
Fig. 2. Functional concordance of putative biomarker discovery methods within the same (DCM vs. NF) dataset. A. GDS2205 dataset. B. GDS2206 dataset. Methods and GO
Biological Process terms are depicted with circles and squares respectively. Lines show signiﬁcant statistical associations between methods and the (top-10) shared GO terms
(FDR 6 0.01). The darker the line the stronger the GO term enrichment detected.
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Fig. 3. Functional concordance of putative biomarker discovery methods within the same ISC vs. NF dataset. A. GSE1869 dataset. B. GSE5406 dataset. Methods and GO
Biological Process terms are depicted with circles and squares respectively. Lines show signiﬁcant statistical associations between methods and the (top-10) shared GO terms
(FDR 6 0.01). The darker the line the stronger the GO term enrichment detected.
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Fig. 4. Functional concordance of putative biomarker discovery methods across datasets. A. DCM vs. NF datasets. B. ISC vs. NF datasets. Datasets and GO Biological Process
terms are depicted with circles and squares respectively. Lines show signiﬁcant statistical associations between datasets and the (top-10) shared GO terms (FDR 6 0.01). The
darker the line the stronger the GO term enrichment detected.
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Fig. 5. Visualization of maximum classiﬁcation performance across different
datasets, model input discovery techniques and model derivation–evaluation
settings. A. DCM vs. NF datasets. B. ISC vs. NF datasets. Heat maps are used to
illustrate the classiﬁcation performance estimated with AUC values. First map
column depicts results from model derivation datasets (with LOOCV). Second
column shows the results from independent evaluations using the complementary
dataset (not used for model derivation). All models were based on linear SVMs. SS:
semantic similarity method, EB: empirical Bayes.
644 F. Azuaje et al. / Journal of Biomedical Informatics 44 (2011) 637–6470.66–0.93 (GSE5406)) were obtained for all methods and datasets.
Perfect discrimination capacity (AUC = 1) was achieved by the
models based on putative biomarkers detected by: kipuMarkers-
2 technique (GDS2205, GDS2206, GSE1869 datasets) using its
top-5 pathway activity levels as inputs; kipuMarkers-1
(GSE1869) using its top-5 pathway activity levels as inputs, GSEA
(GDS2205) using gene expression data from the genes deﬁning
its top-5 pathways, and semantic similarity (GDS2205) using gene
expression data from the top-5 differentially expressed genes and
their corresponding top-5 nearest neighbors (Section 2). Perfect
classiﬁcation performance was also observed from relatively sim-
pler models based on combinations of genes detected by empirical
Bayes: in GDS2205 (inputs: TRMT5, C14orf133, C16orf45, PPP2R4),
GDS2206 (inputs: COPS8, RAB28, SKP1, ACAD10, C5orf23), and
GSE1869 (inputs: STAT6, FCN3, C22orf9, PHLDA1, ENDOGL1,
DEFB126, CCDC93). These representative classiﬁcation perfor-
mances are graphically illustrated in Fig. 5 (ﬁrst column of heat
maps) and described in more detail in Table S5.
3.5. Cross-dataset prediction reproducibility: Independent evaluations
of methods
We assessed the predictive reproducibility of the models re-
ported above through their evaluation on independent datasets,
as speciﬁed in Section 2. Fig. 5 summarizes maximum, representa-
tive results for all putative biomarker discovery methods and data-
sets investigated. The ﬁrst columns of the heat maps depict the
classiﬁcation performance of the models on the derivation dataset
(Section 3.4), while the second columns illustrate the classiﬁcation
performance (AUC) of the resulting models when tested on the
independent dataset. Table S6 shows details of these independent
evaluations. Overall, poor reproducibility of classiﬁcation perfor-
mance was observed. In some cases, classiﬁcation performance
equal or below random classiﬁcation was observed. The maximum
classiﬁcation performance observed in these independent valida-
tions was obtained with the genes retrieved by the semantic sim-
ilarity method (AUC = 0.92, 95% CI: 0.75–1.0), using GSE5406 and
GSE1869 as derivation and independent datasets respectively. This
was followed by the model built with the top-5 pathway activity
indices extracted by the kipuMarkers-v1 technique (independent
evaluation: AUC = 0.90, 95% CI: 0.80–1.0), with GSE1869 and
GSE5406 as derivation and independent datasets respectively.
In the DCM vs. NF classiﬁcation problem (Fig. 5A), the empirical
Bayes and semantic similarity techniques reported the most con-
sistent classiﬁcation performances between derivation and inde-
pendent evaluation results. In the case of the empirical Bayes
method, maximum classiﬁcation performances with AUC = 0.83
(95% CI: 0.67–0.99) and 0.75 (95% CI: 0.5–1.0) were estimated
when GDS2206 and GDS2205 were used as independent datasets
respectively. The most robust prediction performance of the mod-
els based on the biomarkers detected by the semantic similarity
method was observed when using GDS2205 and GDS2206 as der-
ivation and independent datasets respectively (independent evalu-
ation: AUC = 0.87, 95% CI: 0.73–1.0).
In the ISC vs. NF classiﬁcation problem (Fig. 5B), the empirical
Bayes and semantic similarity techniques again provided the
inputs to the most reproducible classiﬁcation models. Similar
classiﬁcation performances were obtained for the model derivation
(LOOCV) and independent evaluations when GSE5406 was used as
the derivation dataset. The models based on inputs from the
empirical Bayes and semantic similarity methods reported
AUC = 0.75 (95% CI: 0.5–1.0) and 0.92 (95% CI: 0.76–1.0)
respectively when tested on the independent dataset. In contrast
to the DCM vs. NF classiﬁcation application, an improvement in
classiﬁcation reproducibility was observed in the case of our
pathway-driven analysis methods. GSEA and kipuMarkers-1showed relatively good reproducibility when using GSE1869 as
derivation dataset (AUC = 0.79, 95% CI: 0.65–0.93, and AUC = 0.90,
95% CI: 0.80–1.0, respectively on independent dataset).
Although the focus of this study was to assess predictive con-
cordance of gene set-based models, we also examined perfor-
mances obtained from single genes detected by empirical Bayes
to expand our comparisons. The vast majority of independent eval-
uations using single-genes reported very low classiﬁcation perfor-
mance. Indeed, most of the top single-genes derived from all
datasets provided classiﬁcation performance equal or close to ran-
dom classiﬁcation (AUC = 0.5) when tested on the independent
datasets. Models independently evaluated on GDS2206 and
GSE1869 illustrated exceptions to this observation. For example,
in the former scenario, those built on single top-genes, such as
TRMT5 and HMGN2, reported AUCP 0.70. Fig. S1 (Supplementary
information) depicts the ROC curves from models based on these
genes.
3.6. Predictive agreement with primary investigations
We examined the papers that originally reported the datasets
investigated here to assess the predictive concordance with our
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plied. The largest agreement in terms of overlapping genes identi-
ﬁed as putative biomarkers was observed between our results and
the research on GSE5406 [39]. The primary research applied Signif-
icance Analysis of Microarray (SAM) to detect potential biomarkers
resulting in 642 differentially expressed genes. We then compared
their signature with our most differentially expressed pathways
detected by kipuMarkers, GSEA and semantic similarity tech-
niques, as well as the differentially expressed genes detected by
empirical Bayes. A total of 102 genes were found in common be-
tween our investigations: 13 genes detected by kipuMarkers, 18
genes included in the pathways detected by GSEA, six from empir-
ical Bayes and seven detected by the semantic similarity method.
We could not compare classiﬁcation performances as the primary
study did not implement this task. Similar comparisons were com-
pleted using the other datasets as follows. Table S7 offers details of
these relationships.
In terms of the putative biomarkers identiﬁed, disagreements
between our analyses and the primary research were observed.
However, there is indication of classiﬁcation performance concor-
dance. In the primary study [37], GDS2205 was analyzed with
SAM and 27 signiﬁcantly differentially expressed genes were de-
tected. Only the GSEA and the kipuMarkers methods reported
genes in common (one gene each from the most signiﬁcant path-
way) with this biosignature. Barth et al. [37] implemented classiﬁ-
cation models with the Prediction Analysis for Microarrays (PAM)
technique, and obtained an average classiﬁcation accuracy of
90%, which is similar to the performances observed above.
GDS2206 showed similar relationships with the original research:
27 differentially expressed genes (SAM), maximum classiﬁcation
accuracy of 90%. In this case the top pathway detected by kipuMar-
kers and the set of most differentially expressed genes found by
empirical Bayes included only one gene (each) in common with
the original report. The primary investigation of GSE1869 [38] re-
ported 31 genes signiﬁcantly differentially expressed using SAM.
Classiﬁcation performance analysis of these potential biomarkers
was not conducted, and their overlap with our top predictions
was small: 1 (GSEA), 2 (kipuMarkers), 1 (empirical Bayes) and 1
(semantic similarity).4. Discussion and conclusions
We investigated the predictive and functional concordance of
ﬁve techniques for the discovery of putative biomarkers, across
independent datasets derived from cardiovascular research stud-
ies. We found little commonality in terms of the genes and gene
sets (pathways) deﬁning the most signiﬁcant, potential biosigna-
tures. This multiplicity of putative biomarkers was also observed
when compared to the original studies reporting the datasets
investigated. Such lack of overlaps has been reported using data
derived from cancer research [27]. We also found that the classi-
ﬁcation performances obtained from this diversity of potential
biosignatures tend to be high when estimated on each dataset.
Such performances were, in general, difﬁcult to replicate in inde-
pendent datasets. However, comparable prediction performances
between derivation and independent validation analyses were ob-
served in some settings, with independent evaluations reporting
AUC > 0.75. This suggests, on one side, the feasibility of success-
fully validating and reproducing prediction results across inde-
pendent datasets. On the other side, our results suggest that
some of our models, and previous research, over-ﬁtted derivation
datasets. Despite this lack of predictive consistency, we also
found that putative biomarker identiﬁcation methods can detect
gene sets signiﬁcantly implicated in common, speciﬁc biological
processes within and across datasets. Moreover, independentstudies (datasets) can be linked through such functional
concordance.
Our results showed that classiﬁcation performance reproduc-
ibility may be inﬂuenced by both the observed multiplicity of po-
tential biomarkers and the sizes of the derivation datasets.
However, we do not have sufﬁcient evidence to suggest that rela-
tive small sizes of data can act as the major cause of lack of repro-
ducibility. In this study, we found that relatively small datasets
could actually offer robust predictions across independent datasets
(e.g. GDS2205). Furthermore, lack of reproducibility can also be ob-
served when using larger model derivation datasets (GSE5406, 124
samples). This adds to the notion that lack of predictive reproduc-
ibility and diversity of putative biomarkers is governed by a variety
of experimental and biological factors. A signiﬁcant amount of this
variability may be explained by the biological redundancy and
complexity inherent in the molecular networks underpinning com-
mon diseases [10]. Potential sources of heterogeneity also involve
the bias and variability added by the classiﬁcation models depend-
ing of dataset sizes and characteristics, as well as the presence of
unknown confounding factors including those related to biomedi-
cal history and sub-phenotypes [30]. Moreover, there are several
experimental factors that go back to the data generation and pre-
processing steps: correlated noise between genes on a microarray
experiment, errors and noise introduced during the sample prepa-
ration and RNA ampliﬁcation phase, and the bias or inconsistencies
contributed by different normalization or pre-processing tech-
niques [29,48]. Also recent research has demonstrated that model
performance and its reproducibility can depend on the clinical
endpoint or class under investigation [32], and that prediction
capability may depend on the combined effect of classiﬁcation
complexity and sample size [49]. These factors may be used to ex-
plain the relative lack of predictive reproducibility and deserve fu-
ture investigations.
In GSE5406, we obtained poor classiﬁcation generalization.
However, we also observed strong overlaps, in terms of putative
biomarkers selected, with the original study that generated this
dataset. Thus, this application may represent an example of a clas-
siﬁcation problem in which data size may not be a dominant factor
to achieve predictive robustness. This is in line with evidence,
including that recently presented by the latest assessment of the
MAQC Consortium [32], that indicates that data size alone may
not always matter. This is supported by the fact that it is possible
to obtain robust models using relatively small datasets, and poor
generalization when using larger datasets. This corroborates the
understanding that predictive reproducibility is a multi-factorial,
complex problem in which multiple technical and domain-speciﬁc
obstacles need to be overcome. For example, recent research based
on a wide variety of dataset sizes also showed that data size should
not be seen as a dominant factor in isolation. In particular, its inter-
play with biological classiﬁcation problem complexity and selec-
tion of prediction end-points has been shown [49].
4.1. Potential biomedical novelty of our results
To estimate the potential biomedical novelty or relevance of our
predictions, we searched the literature and databases for known
gene-disease relationships. Examples of relevant associations de-
tected by the empirical Bayes method include: STAT6 (GSE1869
dataset), which has been linked to myocardial ischemia and reper-
fusion [50], and HMOX2 (GSE5406 dataset) with no established
connection to HF, but which is known to be induced by oxidative
stress and inﬂammation [51]. GSEA detected the SIG_PIP3 path-
way, which is a 63-gene signaling pathway implicated in cardiac
myocytes, as signiﬁcantly differentially regulated in GSE5406
(FDR = 0.001). In GDS2205, the semantic similarity method identi-
ﬁed a number of deregulated genes known to be involved in heart
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opment [52], and KLF5 has been associated with cardiac hypertro-
phy and ﬁbrosis [53]. In GDS2205, kipuMarkers-v1 indentiﬁed the
acetaminophen pathway as the most differentially deregulated
pathway (Table S1). Previous research in animal models suggested
acetaminophen as a safe drug in the context of post-myocardial
infarction, though no major cardioprotective properties were ob-
served [54]. In GSE5406, the Reck pathway was identiﬁed by kipu-
Markers-2 as a top putative target (Table S1). This pathway is
responsible for membrane-anchored inhibition of matrix metallo-
proteinases, including MMP9 and TIMP1, which have been associ-
ated with heart failure [55].
4.2. Limitations
The size and depth of predictions examined may be seen as a
possible limitation of our study. We reported ﬁndings that focused
on the most signiﬁcant gene sets and pathways detected. This
means that potentially relevant groups of genes could have been
ignored. However, by concentrating on our top predictions we also
aimed to reduce the potential number of false positive associa-
tions. Moreover, we were interested in investigating biosignatures
that were identiﬁed as the most biologically-promising or statisti-
cally-supported by the methods evaluated.
Also we are naturally limited by the quality and coverage of the
molecular pathways used in our analysis. Nevertheless, we aimed
to discover putative pathway-based biomarkers using annotated,
experimentally-validated gene sets. Moreover, we also incorpo-
rated a discovery method fully driven by linear models of available
data, which does not rely on pathways selected a priori. In any case
there is a need to implement comparisons between network-based
methods that are not based on pre-deﬁned gene sets, such as those
reported in [12,18,19,58,59]. Future studies may also include alter-
native gene set discovery techniques, such as those reviewed in
[60].
Another constraint may be represented by our emphasis on
classiﬁcation models based on SVM. However, we did not intend
to perform a comprehensive comparison of classiﬁcation tech-
niques in gene expression data, which has been reported elsewhere
[56,57], and therefore decided to focus on a known powerful and
robust approach [56]. Future research could provide deeper views
of predictive concordance with an emphasis on classiﬁcation mod-
el diversity. We also acknowledge that future investigations in the
area of cardiovascular diseases should include other datasets and
clinical conditions aside from heart failure.
Gene set selection for classiﬁcation was performed on the der-
ivation datasets, and the classiﬁcation performance of the resulting
sets was then tested on the independent evaluation datasets,
which were not used in the prior phase. The LOOCV was used to
provide estimates of classiﬁcation performance of selected bio-
markers within the derivation dataset only. Also note that the
selection of biomarkers within the derivation datasets was not
wrapped around the classiﬁers implemented. Regardless of these
bias prevention strategies, we acknowledge that the use of LOOCV
may have contributed to a biased estimate of the classiﬁcation per-
formance assigned to models within the derivation datasets only.
However, also note that in some of the classiﬁcation applications
we obtained relatively consistent classiﬁcation performances
across derivation-independent datasets, which suggest that at least
in some cases the estimates were not overoptimistic.
Another critical research topic is to assess how data pre-
processing can inﬂuence gene set or network-based biomarker dis-
covery. In this research, we used data already normalized by the
original studies. This allowed us to make comparisons with the
original research’s ﬁndings. Future studies will require the use of
raw data ﬁles to estimate pre-processing effects. Moreover, theimportance of applying a common normalization procedure across
dataset merits consideration [61].5. Conclusions
We offered evidence that a diversity of putative biomarker dis-
covery methods and derived sets of biosignatures detected in inde-
pendent datasets can point to common molecular mechanisms,
which may characterize or control clinical phenotypes. This was
demonstrated within and between independent datasets. How-
ever, a less clear picture is revealed with regard to classiﬁcation
performance reproducibility across and within datasets. In this
case, discrepancies and lack of predictive generalization was a
common theme, though some methods and datasets showed to
be the exception. Partial overlaps and consistency were also found
in relation to the studies originally reporting the datasets.
To the best of our knowledge, this is the ﬁrst functional and
predictive concordance analysis performed using independent
datasets in the area of human heart failure. In particular, we
addressed the problem of pathway-based functional concordance
and of classiﬁcation performance reproducibility in the speciﬁc
context of gene set discovery. Despite the limitations and con-
straints of gene set analysis techniques, they represent useful tools
for suggesting putative biomarkers and for supporting the elucida-
tion of key mechanisms with promising causal or correlative
implications. The successful independent validation of disease bio-
marker models may be beneﬁted by considering multiple discov-
ery techniques, and by ensuring that common data acquisition
and pre-processing standards are applied across research sites.
Furthermore, new strategies will be required to manage the intrin-
sic, biological variability encoded in the underlying mechanisms of
complex common diseases. This may require moving from the idea
of detecting differentially expressed genes or pathways, to strate-
gies speciﬁcally aiming to infer genes with potential causal roles,
such as those acting as master regulators.
To sum up our ﬁndings, different ‘‘gene set’’ methods for discov-
ering putative biomarkers can provide concordant predictions in
the sense that they can point to common critical molecular path-
ways underlying the disease investigated. However, in terms of
classiﬁcation performance this consistency is less clear. This sug-
gests that additional research is needed about approaches to incor-
porate ‘‘gene set’’ analysis for disease classiﬁcation, such as the
measurement of integrated pathway expression activity.6. Conﬂict of interest
None declared.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.jbi.2011.02.003.
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